Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

46 Press Releases
DateTitleCompany
24 Jul 14 BioAlliance Pharma: Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen BioAlliance Pharma,
Published by
Business Wire
03 Jul 14 BioAlliance Pharma: FDA approval of Beleodaq™ (belinostat) Bioalliance Pharma,
Published by
Business Wire
30 Jun 14 Bioalliance Pharma and Topotarget Shareholders Approve Proposed Cross-Border Merger to Create Onxeo Bioalliance Pharma,
Published by
Business Wire
10 Jun 14 BioAlliance Pharma Strengthens Livatag® pAtent Protection in Japan Until 2032 BioAlliance Pharma,
Published by
Business Wire
31 Mar 14 BioAlliance Pharma Collaborates with Penn Pharma on the Industrial Development of Validive® BioAlliance Pharma,
Published by
Business Wire
04 Feb 14 BioAlliance Pharma’s Partner, Sosei, Announces a Partnership With FUJIFILM Pharma for Commercialization Rights for Loramyc® in Japan BioAlliance Pharma,
Published by
Business Wire
14 Nov 13 BioAlliance Pharma Strengthens Sitavig Patent Protection with New U.S. and South Korean issued Patents BioAlliance Pharma,
Published by
Business Wire
30 Sep 13 BioAlliance Pharma : First Meeting of the International Advisory Board on Oral Mucositis and Development of Validive® BioAlliance Pharma,
Published by
Business Wire
27 Jun 13 BioAlliance Pharma Announces Shareholders’ Meeting and Appointment of Russell Greig and Danièle Guyot-Caparros as Independant Board Members BioAlliance Pharma,
Published by
Business Wire
15 Apr 13 BioAlliance Pharma’s Sitavig® Receives Market Authorization in the US For the Treatment of Herpes Labialis BioAlliance Pharma,
Published by
Business Wire
12 Mar 13 BioAlliance Pharma Pursues the Development Plan of Its Loramyc® in Japan Through Its Partner Sosei BioAlliance Pharma,
Published by
Business Wire
21 Dec 12 BioAlliance Pharma Announces the Registration of Sitavig® in European Countries BioAlliance Pharma,
Published by
Business Wire
20 Dec 12 BioAlliance Pharma: First Meeting of the DSMB of the ReLive Trial and Continuation without Modification of the Phase III Clinical Trial with Livatag® in Primary Liver Cancer BioAlliance Pharma,
Published by
Business Wire
24 Sep 12 BioAlliance Pharma announces the execution of its licensing agreement with Vestiq Pharmaceuticals for Oravig® in the US BioAlliance Pharma,
Published by
Business Wire
18 Jun 12 BioAlliance Pharma Reinforces Its Development Team with the Appointment of Louis Kayitalire, MD, as Head of Research and Development BioAlliance Pharma,
Published by
Business Wire
13 Jun 12 BioAlliance Pharma and Teva Announce First License Agreement for Sitavig® for Israel BioAlliance Pharma,
Published by
Business Wire
01 Jun 12 BioAlliance Pharma: Combined Shareholders Meeting BioAlliance Pharma,
Published by
Business Wire
26 Apr 12 BioAlliance Pharma Announces Two New Key Steps in the Development of Its AMEP® Biotherapy BioAlliance Pharma,
Published by
Business Wire
28 Jul 11 Q2 2011: BioAlliance Pharma Accelerates the Progress of Its “Orphan Oncology Products” Portfolio and Pursues Its International Partnerships on Its “Specialty Products” BioAlliance Pharma,
Published by
Business Wire
01 Aug 11 BioAlliance Pharma Initiates the Clinical Batches Production of Livatag® (Doxorubicin Transdrug™) for its Phase III Clinical Trial BioAlliance Pharma,
Published by
Business Wire
06 Sep 11 BioAlliance Pharma: Presentation of Livatag® survival results at the international liver cancer congress in Hong Kong BioAlliance Pharma,
Published by
Business Wire
01 Jun 11 BioAlliance Pharma filed an appeal to the French Supreme Court contesting a preliminary procedural decision on jurisdiction in the arbitration against SpePharm and SpeBio BioAlliance Pharma,
Published by
Business Wire
24 Jun 11 BioAlliance Pharma Submits Application for Orphan Medicinal Product Designation for Clonidine Lauriad™ in Europe and the United States BioAlliance Pharma,
Published by
Business Wire
23 Jan 12 BioAlliance Pharma Announces Two Key Steps with Its AMEP™ Biotherapy for Metastatic Melanoma BioAlliance Pharma,
Published by
Business Wire
26 Jan 12 2011 Achievements and 2012 Prospects BioAlliance Pharma Confirms the Dynamics of Its Core Business BioAlliance Pharma,
Published by
Business Wire
01 Feb 12 To Gain a Better Understanding of the Company, Its Product Portfolio and Its Management Team, BioAlliance Pharma Organizes a Symposium "Oncology: Key Issues for the Future" BioAlliance Pharma,
Published by
Business Wire
27 Jun 11 BioAlliance Pharma Submits a Phase III Clinical Trial Application for Livatag® (doxorubicin Transdrug™) to the French Drug Agency (Afssaps) BioAlliance Pharma,
Published by
Business Wire
04 Jan 12 BioAlliance Pharma: New Achievements in the Collaboration with Its Strategic European Partner, Therabel BioAlliance Pharma,
Published by
Business Wire
18 Nov 11 BioAlliance Pharma Ranked as France's Fastest Growing Company in the 2011 « Deloitte Technology Fast 50 » BioAlliance Pharma,
Published by
Business Wire
18 Apr 12 BioAlliance Pharma: Full-Year Financial Results for 2011 BioAlliance Pharma,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.